Summary of COVID-19 vaccine candidates and related agreements This table tracks various development, production, supply, funding, and intellectual property agreements for COVID-19 vaccine candidates. The information included in the table was sourced from publicly available information such as company websites and reputable news sources. In addition, the WHO Draft Landscape of COVID-19 Candidate Vaccines was used as a central reference point to identify new vaccine candidates. Please note: the contents of this table are formed from GHIAA’s understanding and interpretation of publicly available information. The purpose of this table is to begin to identify agreements related to the COVID-19 response, however it should not be relied upon to provide a complete overview of the current landscape. Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology AZD1222 (previously Jenner Institute, University Phase 3 clinical trial UK Government Supply agreement between AstraZeneca & Inclusive ChAdOx1) of Oxford (academic (government) Vaccines Alliance Non-Replicating Viral Vector institution) ISRCTN Registry Identifier: University of Oxford ISRCTN89951424 (Phase 3) Licensing, manufacturing, and distribution agreement AstraZeneca (multinational (academic institution) between R-Pharm and AstraZeneca pharmaceutical company) ClinicalTrials.gov Identifiers BARDA (government) Serum Institute of India (U.S.): Supply agreement between Symbiosis CEPI (funder) (vaccine manufacturer) NCT04456595 (Phase 3) Pharmaceutical and AstraZeneca NCT04352608 (Phase 1/2) Gavi, the Vaccine IQVIA (contract research NCT04383574 (Phase 1/2) Alliance (multilateral Supply agreement for 300 million doses between U.S. organization) organization) Government and AstraZeneca EU Clinical Trials Register Identifier: 2020-001228-32 Supply agreement for100 million doses (30 million by (Phase 2b/3) Sept. 2020) between U.K. Government and 2020-001072-15 (Phase AstraZeneca 1/2) Supply/manufacturing agreement between Brazilian Pan African Clinical Trials Government and AstraZeneca Registry Identifier: PACTR202006922165132 Manufacturing agreement between AstraZeneca & (Phase 1/2) Catalent Supply & licensing agreement between Serum Institute of India and AstraZeneca Manufacturing agreement for clinical trials between Serum Institute of India and AstraZeneca Researched by: Nathan Gardner 1 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Manufacturing, procurement and distribution agreement for 300 million doses between CEPI, Gavi, and AstraZeneca Manufacturing agreement (1-year) between Oxford Biomedica & AstraZeneca Funding partnership between BARDA and AstraZeneca Funding partnership between CEPI, Gavi, and AstraZeneca Development agreement between Oxford & AstraZeneca Development collaboration between IQVIA & AstraZeneca mRNA-1273 Moderna (biotechnology Phase 3 clinical trial NIAID (government) 10-year strategic collaboration agreement between LNP-encapsulated mRNA company) Moderna & Lonza BARDA (government) ClinicalTrials.gov Identifiers Lonza (multinational (U.S.): CEPI (funder) Funding partnership between Moderna & CEPI pharmaceutical company) NCT04283461 (Phase 1) Operation Warp Speed NIAID (government) NCT04405076 (Phase 2) Funding partnership between Moderna & BARDA (government) NCT04470427 (Phase 3) Manufacturing agreement between Moderna & Laboratorios Farmacéuticos Rovi Inactivated vaccine Wuhan Institute of Phase 3 clinical trial Biological Products (state- owned biotechnology Chinese Clinical Trials company) Registry Identifiers: ChiCTR2000031809 (Phase Sinopharm (state-owned 1/2) biotechnology company) Researched by: Nathan Gardner 2 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology ChiCTR2000034780 (Phase 3) Inactivated vaccine Beijing Institute of Biological Phase 3 clinical trial Products (state-owned biotechnology company) Chinese Clinical Trials Registry Identifier: Sinopharm (state-owned ChiCTR2000032459 (Phase biotechnology company) 1/2) ChiCTR2000034780 (Phase 3) CoronaVac Sinovac (state-owned Phase 3 clinical trial Advantech Capital Development agreement between Sinovac & Instituto Inactivated + alum biotechnology company) (general industry) Butatan ClinicalTrials.gov Identifiers Instituto Butatan (research Vivo Capital (general (U.S.): Clinical trial and manufacturing agreement between institute) industry) NCT04456595 (Phase 3) Sinovac & PT BioFarma NCT04352608 (Phase 1/2) Government of China NCT04383574 (Phase 1/2) (government) Bacillus Calmette-Guerin University of Melbourne Phase 2/3 clinical trial Gates Foundation Funding agreement between Gates and University of (BCG) live-attenuated vaccine (academic institution) (funder) Melbourne ClinicalTrials.gov Identifiers Murdoch Children’s Sarah and Lachlan (U.S.): Research Institute (research Murdoch (funder) NCT04327206, institute) NCT04328441 The Royal Children’s Radboud University Medical Hospital Foundation Center (non-profit) (non-profit) Faustman Lab at The Minderoo Massachusetts General Foundation (non-profit) Hospital (research institute) South Australian government (funder) NAB Foundation (non- profit) Researched by: Nathan Gardner 3 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Calvert-Jones Foundation (non-profit / funder) HUG Foundation (non- profit / funder) River Capital (general industry) Individual donors BNT162b2 Pfizer (multinational Phase 2/3 clinical trial Material transfer and Collaboration agreement LNP-mRNA pharmaceutical company) between Pfizer & BioNTech EU Clinical Trials Register BioNTech (biotechnology Identifier: 2020-001038-36 Licensing & equity investment agreement between company) (Phase 1/2) Fosun and BioNTech Fosun Pharma (multinational ClinicalTrials.gov Identifier Supply agreement for 100 million doses between U.S. pharmaceutical company) (U.S.): NCT04368728 (Phase Government, Pfizer & BioNTech 1/2) Supply agreement for 120 million doses between Chinese Clinical Trial Government of Japan, Pfizer, & BioNTech Registry Identifier: ChiCTR2000034825 (Phase Clinical trial agreement between Pfizer, BioNTech, 1/2) The University of Rochester Medical Center and Rochester Regional Health Adjuvanted recombinant Anhui Zhifei Longcom Phase 2 clinical trial Development partnership between Anhui Zhifei protein (RBD-Dimer) Biopharmaceutical Longcom Biopharmaceutical & Institute of Protein Subunit (biotechnology company) ClinicalTrials.gov Identifier Microbiology, Chinese Academy of Sciences (U.S.): Institute of Microbiology, NCT04445194 (Phase 1) Chinese Academy of NCT04466085 (Phase 2) Sciences (academic institution) Researched by: Nathan Gardner 4 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology Ad5-nCoV CanSino Biologics Phase 2 clinical trial Development agreement between National Research Adenovirus Type 5 Vector, (biotechnology company / Council Canada & CanSino Biologics Non-Replicating Viral Vector vaccine manufacturer) Chinese Clinical Trial Registry Identifiers: Development agreement between Sartorius, Beijing Beijing Institute of ChiCTR2000030906 (Phase Institute of Biotechnology & CanSino Biologics Biotechnology (academic 1), ChiCTR2000031781 institution) (Phase 2) 2014 Licensing agreement (between CanSino and National Research Council Canada – for cell line) ClinicalTrials.gov Identifier (U.S.): NCT04313127 NVX-CoV2373 Novavax (biotechnology Phase 1/2 clinical trial Operation Warp Speed Manufacturing agreement between AGC Biologics & Full length recombinant SARs company) (government) Novavax CoV-2 glycoprotein ClinicalTrials.gov Identifier CEPI (funder) nanoparticle vaccine (U.S.): Funding agreement between Novavax and the U.S. adjuvanted with Matrix M – NCT04368988 (Phase 1/2) U.S. Department of Department of Defense Protein Subunit Defense (government) Funding agreement between Novavax and CEPI Funding agreement including the delivery of 100 million doses starting late 2020 between Operation Warp Speed and Novavax Contract development and manufacturing agreement between Emergent & Novavax Phase 1 clinical trial agreement between Nucleus & Novavax ZyCoV-D: DNA plasmid Cadila Healthcare Limited Phase 1/2 clinical trial vaccine (multinational pharmaceutical company) Chinese Clinical Trial Registry Identifier: Researched by: Nathan Gardner 5 Last update date: August 1, 2020 Vaccine Developer(s) Current development stage Funders Related agreements/partnerships/collaborations candidate/technology CTRI/2020/07/026352 (Phase 1/2) DNA plasmid vaccine Osaka University (academic Phase 1/2 clinical trial Collaboration between Osaka University, AnGes & institution) Takara Bio Japanese Clinical Trial AnGes (biotechnology Identifier: Manufacturing agreement between Cytiva & Takara company) JapicCTI-205328 (Phase I) Bio Takara Bio (biotechnology company) ClinicalTrials.gov Identifier (U.S.): NCT04463472 (Phase 1/2) Inactivated vaccine Institute of Medical Biology, Phase 1/2 clinical trial Jack Ma Foundation Chinese Academy of (funder) Medical Sciences (academic ClinicalTrials.gov Identifiers institution) (U.S.): NCT04412538 (Phase I) NCT04470609 (Phase 1/2) RBD-based vaccine Kentucky Bioprocessing,